Category: 187834-88-4

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.187834-88-4,1-Boc-isonipecoticacidhydrazide,as a common compound, the synthetic route is as follows.

To triphosgene (355 mg) was added methylene chloride (3 ml) . To the mixture were added dropwise 3- chloroindazole (458 mg) and triethylamine (1.95 ml) dissolved in methylene chloride (3 ml) with stirring at 0C The reaction solution was warmed to room temperature, stirred for 30 minutes, and then cooled to 0C again. To the reaction solution were added dropwise tert-butyl 4- (hydrazinecarbonyl) iperidine-l-carboxylate (730 mg) and triethylamine (0.63 ml) dissolved in methylene chloride (3 ml) , and the mixture was stirred at room temperature for 4 hours. To the reaction solution was added saturated sodium carbonate aqueous solution, and the resultant solution was extracted with chloroform. The organic layer was dried over sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica-gel chromatography (developing solvent: chloroform / methanol = 95/5) to give tert-butyl 4-({2-[.(3- chloro-lH-indazol-1- yl) carbonyl] hydrazinyljcarbonyl) piperidine-l-carboxylate (519 mg) .LC-MS, m/z; 422 [M+H] +, 187834-88-4

The synthetic route of 187834-88-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DAINIPPON SUMITOMO PHARMA CO., LTD.; MIZUNO, Kazuhiro; IKEDA, Junya; NAKAMURA, Takanori; IWATA, Masato; OTAKA, Hiromichi; GOTO, Nana; WO2012/169649; (2012); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.187834-88-4,1-Boc-isonipecoticacidhydrazide,as a common compound, the synthetic route is as follows.

3-phenyl-2-(4-{ [4-(5-pyrimidin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl} phenyl)-l,6-naphthyridin-5(6H)-one hydrochloride (6-54) 2-(3-piperidin-4-yl-lH-l,2,4-triazol-5-yl)pyrimidine (B)A mixture of tert-butyl 4-(hydrazinocarbonyl)piperidine-1-carboxylate (10.1 g, 41.5 mmol) and 2-cyanopyrimidine (4.36 g, 41.5 mmol) in 1-butanol (20 mL) was heated to reflux for 48 hours. The mixture was concentrated, suspended in ether, and filtered to give tert-butyl 4-(5-pyrimidin-2- yl-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate as a solid. MS (M+Eta1″): 331.2 observed; 1H-NMR (400 MHz, CD3OD): delta 8.92 (d, J=4.0Hz, 2H), 7.52 (t, J=4.0Hz, IH), 4.18-4.15 (m, 2H), 3.14-3.08 (m, IH), 2.98 (br.s, 2H), 2.07-2.01 (m, 2H), 1.85-1.77 (m, 2H), 1.48 (s, 9H)., 187834-88-4

The synthetic route of 187834-88-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK & CO., INC.; WO2006/65601; (2006); A2;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

187834-88-4, 1-Boc-isonipecoticacidhydrazide is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of Compound [CCCX1H] (600 mg, 2.47 mmol), Compound [CCCXTV] (291 mg, 2.47 mmol), and sodium methoxide (266 mg, 25 wt% solution in methanol) in 2-ethoxyethanol (6 mL) was heated at 125 C for 16 h. The reaction mixture was partitioned between EtOAc and saturate aqueous ammonium chloride solution. The aqueous layer was extracted with additional EtOAc. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The crude material was purified by ISCO to obtain Compound [CCCXVJ as a colorless oil (73.3 mg, 9%). 1H NMR (400 MHz, CHLOROFORM-d) delta ppm 1.57 (s, 9 H) 1.77 – 1.95 (m, 2 H) 2.09 (d, J=2.44 Hz, 2 H) 2.62 (s, 3 H) 2.89 – 3.01 (m, 2 H) 3.06 (br. s., 1 H) 3.98 – 4.51 (m, 2 H) 7.22 (d, J=4.59 Hz, 2 H) 8.50 (d, >;4.93 Hz, 2 H) 9.07 (br. s., 1 H).

187834-88-4, 187834-88-4 1-Boc-isonipecoticacidhydrazide 22713165, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; MERCK SHARP &; DOHME CORP.; BANYU PHARMACEUTICAL CO., LTD.; FAN, Weiming; HAXELL, Thomas, F. N.; JENKS, Matthew, G.; KAWANISHI, Nobuhiko; LEE, Shuliang; LIU, Hao; MALASKA, Michael, J.; MOORE, Joseph, A., III; OGINO, Yoshio; ONOZAKI, Yu; PANDI, Bharathi; PEEL, Michael, R.; SAKAMOTO, Toshihiro; SIU, Tony; WO2010/104933; (2010); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem